Biologically derived Medicines on Demand | Apply Online

Bio MOD (Biologically derived Medicines on Demand) Grant Opportunity FAQs

1) What is the Bio MOD grant opportunity?

Bio MOD (Biologically derived Medicines on Demand) was a DARPA Defense Sciences Office research and development grant opportunity under Broad Agency Announcement (BAA) DARPA BAA 11-71. The effort focused on enabling rapid, on-site production of multiple protein-based biologic medicines tailored to urgent battlefield medical situations.

2) What problem was Bio MOD trying to solve?

The program aimed to reduce reliance on traditional, centralized pharmaceutical manufacturing by enabling forward-deployed medical personnel to produce needed protein biologics on demand near the point of care. This was intended for austere, fast-changing environments where the exact therapeutic need may not be known in advance and where resupply or cold-chain logistics may be limited or unreliable.

3) What types of medicines did the program focus on?

Bio MOD specifically focused on protein-based biologic medicines (protein therapeutics).

4) What does "on-demand" mean in the context of Bio MOD?

"On-demand" refers to producing biologic therapeutics when a need arises, rather than pre-manufacturing and shipping them through traditional supply chains. The goal was rapid production close to the point of care to respond to emergent conditions.

5) What was the intended operational setting for the technology?

The program emphasized battlefield and far-forward medical scenarios, including austere environments with uncertain medical needs and constrained logistics.

6) What were the two main technical development areas targeted by Bio MOD?

Bio MOD targeted two tightly linked areas:

• Flexible approaches to genetic engineering and strain/system modification to enable synthesis of multiple protein therapeutics across different production hosts.
• Flexible, portable device platforms capable of manufacturing these biologics in the field while meeting demanding product characteristics and timelines.

7) What kinds of production hosts were contemplated?

The opportunity referenced a variety of production hosts, including engineered microbial strains, engineered eukaryotic strains, and cell-free expression systems.

8) Why did DARPA emphasize producing multiple therapeutics rather than a single drug?

The program concept emphasized flexibility and multiplicity so platforms could be reconfigured and pivot quickly to produce different protein biologics depending on the threat, injury pattern, or medical requirement encountered in theater.

9) What does "reconfigurable" mean for this program?

Based on the description, "reconfigurable" refers to biology and manufacturing methods that can be adjusted to produce different protein therapeutics, rather than being locked into a single-purpose manufacturing approach for one product.

10) What performance characteristics did DARPA call out for the biologics produced in the field?

DARPA explicitly called for high purity, efficacy, and potency, and for production within short timeframes when a need arises.

11) Was the program only about making the protein, or about full manufacturing?

The description points to an end-to-end field manufacturing concept. The goal was not just expressing a protein, but using a platform that could manage controlled synthesis, processing, and quality-related considerations sufficiently to yield a usable therapeutic product.

12) What kind of device platform was DARPA looking for?

DARPA sought flexible and portable device platforms that could manufacture protein-based biologics in the field and still meet demanding requirements for product characteristics and speed.

13) Which DARPA office issued this opportunity?

The opportunity was issued by DARPA's Defense Sciences Office.

14) What was the solicitation or announcement identifier?

The opportunity was associated with Broad Agency Announcement DARPA BAA 11-71.

15) How was the opportunity categorized for funding and reporting purposes?

Administratively, it was categorized as discretionary and listed under the Science and Technology and other Research and Development activity category.

16) What CFDA number was listed for this opportunity?

The listed CFDA number was 12.910 (Research and Technology Development).

17) What funding instrument types could DARPA use for Bio MOD awards?

DARPA indicated multiple possible instrument types, including cooperative agreements, grants, and other procurement contracts. This reflects DARPA's practice of selecting the mechanism that best fits the technical and programmatic needs.

18) Was there a cost sharing or matching requirement?

No cost sharing or matching requirement was noted in the provided information.

19) Who was eligible to apply?

Eligibility was described as unrestricted, meaning it was broadly open to applicants of any entity type, subject to any clarifications in the full announcement text.

20) When was the opportunity posted and when did it close?

The solicitation cycle reflected in the listing was from 2011. It was posted on August 30, 2011, with an original closing date of November 15, 2011, and it was archived shortly thereafter.

21) Where could applicants find the full details of the opportunity?

The listing referenced an additional information link pointing to the full DARPA BAA 11-71 announcement.

22) Who was the point of contact mentioned for access issues?

The listing provided contact through a BAA Coordinator for access issues.

23) What was the overall goal or end state of Bio MOD?

The intended end state was a compact, deployable capability that could support front-line medics and far-forward care settings by generating protein-based biologics as needed in response to emergent conditions, improving medical responsiveness and preparedness.